Savolitinib vs Telisotuzumab Vedotin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
Reported efficacy
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized): SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. (met)
Result source: NCT05261399
Telisotuzumab Vedotin
Marketed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07323641 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Savolitinib | Telisotuzumab Vedotin |
|---|---|---|
| PFS, median | 8.2 vs 4.5avs chemotherapyNCT05015608 | —Trial running · NCT04928846 |
| OS, median | —Not posted · NCT04923945 | —Trial running · NCT04928846 |
| ORR | 62.1%abNCT049239451 other result
| —Trial running · NCT04928846 |
| Duration of response, median | —Not posted · NCT04923945 | —Trial running · NCT04928846 |
PFS, median
- Savolitinib
- 8.2 vs 4.5avs chemotherapyNCT05015608
- Telisotuzumab Vedotin
- —Trial running · NCT04928846
OS, median
- Savolitinib
- —Not posted · NCT04923945
- Telisotuzumab Vedotin
- —Trial running · NCT04928846
ORR
- Savolitinib
- 62.1%abNCT04923945
1 other result
- 39.2% NCT04923945
- Telisotuzumab Vedotin
- —Trial running · NCT04928846
Duration of response, median
- Savolitinib
- —Not posted · NCT04923945
- Telisotuzumab Vedotin
- —Trial running · NCT04928846
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Telisotuzumab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Savolitinib
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Savolitinib's landscape · Telisotuzumab Vedotin's landscape